Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Stopped early · Phase 4

Conditions studied: Age-Related Macular Degeneration

In brief

The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.

Key facts

Study ID

NCT00134667

Run by

Eyetech Pharmaceuticals

People needed

360

Starts

2005-03-01

Expected to finish

2008-10-01

Last updated by the study team

2007-01-15

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects of either gender; aged 50 years or greater.
• Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic lesion composition
• Best corrected visual acuity in the study eye between 20/40 and 20/200

You may not qualify if…

• Any prior PDT with Visudyne to the study eye
• Any previous AMD thermal laser therapy to the study eye

Where it is running

• Retina Centers, P.C., Northwest Location — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.